Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

DNA markers for management of cancer

a technology of dna markers and cancer, applied in the field of molecular biology and oncology, can solve the problems of inconvenient cytologic analysis of many cytologic samples, difficult to accurately analyze many cytologic samples, and poor overall prognosis, so as to improve the staging of the disease and monitoring, and the effect of minimal invasiveness

Inactive Publication Date: 2010-12-30
HOON DAVE S B +1
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention is based on the discovery that DNA markers can be detected in cell-free bone marrow samples and used for cancer diagnosis, staging, and prognosis. These markers include LOH, hypermethylation, and mutation, which can be used alone or in combination to provide a more sensitive and precise diagnosis, staging, and prognosis of cancer than using individual markers. The invention provides methods for detecting these markers and kits for implementing them. The technical effect of the invention is the improved ability to diagnose, stage, and prognose cancer using cell-free bone marrow samples."

Problems solved by technology

Once metastases are clinically apparent, overall prognosis is poor.
Historically, conventional cytologic assessment of blood and bone marrow (BM) aspirates has been performed with limited success (Molino et al 1991 and Beiske et al 1992).
However, the accurate microscopic analysis of many cytologic samples requires considerable cytopathologic expertise and can be tedious, particularly if performed serially to assess disease progression and / or response to treatment.
Finally, these assay systems cannot characterize the biologic behavior of the cells being detected and thus many may represent dormant tumor cells, apoptotic cells, nonpathologic tumor cells, or displaced normal breast epithelial cells.
However, the examination of an excised primary tumor specimen may be of limited value in that it provides information of those genetic events that have occurred and not ongoing alterations which may be of clinical relevance, either prognostically or for therapeutic decisions.
Although, BM is a common site for recurrence of some types of cancer, such as breast and prostate cancer, to date, BM has not been studied for the presence of suitable genetic markers.
The hypermethylation of CpG islands of promoter regions of TSG is quite common and is a significant genetic aberration for tumor cells to shut off TSG expression.
Majority of these studies have been focused on carcinomas; there are limited studies in cutaneous melanomas and other types of cancers.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • DNA markers for management of cancer
  • DNA markers for management of cancer
  • DNA markers for management of cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

Identification of Circulating Tumor-Associated Epigenetic Alterations in the Bone Marrow from Breast Cancer Patients Using a Hypermethylation Gene Panel

Introduction

[0071]A variety of genetic alterations including microsatellite instability, allelic loss, and mutation have been described in primary breast cancers. These events result in loss of gene function and have been implicated in tumor development and progression. Clinical tools (i.e., radiographic) used to detect breast cancer progression have been limited particularly in the era of earlier disease diagnosis. The most sensitive method for the identification of breast cancer progression at the time of patient diagnosis is histopathologic lymph node evaluation. However 20-30% of node-negative breast cancer patients will develop recurrent disease within 10 years (Fisher et al 1989 and Rosen et al 1989). Therefore, recurrence may be considered a consequence of occult metastasis not detected at the time of patient diagnosis and tre...

example 2

Distinct Hypermethylation Profile of Primary Breast Cancer is Associated with Sentinel Lymph Node Metastasis

Introduction

[0088]Improved access to mammography and increased patient awareness in breast cancer screening have resulted in a dramatic increase in the detection of early breast cancers (Cady et al 1996; Shapiro 1982; Tabar 1985; and Miller et al 1993). As important, at the time of breast cancer diagnosis, is the identification of concurrent metastatic disease for accurate patient staging and therapeutic decision making. Axillary lymph node dissection (ALND) has provided an invaluable approach to assess for the presence of tumor cell metastasis, particularly in early disease states where standard radiographic imaging is less sensitive. However, ALND can be associated with considerable morbidity including lymphedema and reduced shoulder mobility (Ivens et al 1992 and Warmuth et al 1998). In addition, ALND often requires general anesthesia, in patient hospitalization and a posto...

example 3

Profiling Epigenetic Inactivation of Tumor Suppressor Genes in Tumors and Plasma From Cutaneous Melanoma Patients

Introduction

[0110]Epigenetic events in the form of hypermethylation of TSG promoter region(s) CpG islands can play a role in the development and progression of various cancers (Baylin et al 2000; Esteller et al 2001; Jones et al 2002; and Sidransky et al 2002). The detection of hypermethylated genes in tumors has become important in assessing the mechanisms of known and candidate TSG inactivation. Genes can be transcriptionally silenced when their promoter region(s) CpG islands are hypermethylated (Jones et al 2002). Recent studies have shown this is a significant mechanism whereby TSG expression is shut off in cancer cells (Baylin et al 2000; Esteller et al 2001; Jones et al 2002; Sidransky et al 2002). The hypermethylation status of several known or candidate TSG promoter regions has been profiled for a number of cancers (Esteller et al 2002; Harden et al 2003; Jeronimo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
temperaturesaaaaaaaaaa
temperaturesaaaaaaaaaa
Login to View More

Abstract

A method is provided for assessing allelic losses and hypermethylation of genes in CpG tumor promotor region on specific chromosomal regions in cancer patients, including melanoma, neuroblastoma breast, colorectal, and prostate cancer patients. The method relies on the evidence that free DNA and hypermethylation of genes in CpG tumor promotor region may be identified in the bone marrow, serum, plasma, and tumor tissue samples of cancer patients. Methods of melanoma, neuroblastoma, colorectal cancer, breast cancer and prostate cancer detection, staging, and prognosis are also provided.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 10 / 809,965, filed Mar. 25, 2004, which claims priority to U.S. Provisional Application Ser. No. 60 / 457,395, filed Mar. 25, 2003. The content of both applications is incorporated herein by reference in its entirety.GOVERNMENT SUPPORT[0002]This invention was made with support in part by grants from NCI (Grant Nos. R21 CA100314, PO CA 29605 Project II, and PO CA 13917 Project II), Gonda Foundation, USA DOD Breast Cancer Research Grant, California Breast Cancer Research Grant, and Roy E Coates Foundation. Therefore, the U.S. government has certain rights in the invention.FIELD OF THE INVENTION[0003]The present invention is related to the fields of molecular biology and oncology and provides methods for diagnosis, staging and monitoring of cancer patients.BACKGROUND OF THE INVENTION[0004]Bone Marrow is the most frequent site of the systemic spread of some types of cancer, including breast (Ab...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/68G01N33/53A61BC07H19/00C12P19/34
CPCC12Q1/6806C12Q1/6886Y10T436/143333C12Q2600/118C12Q2600/154C12Q2600/112
Inventor HOON, DAVE S.B.TABACK, BRET
Owner HOON DAVE S B
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com